dc.creator | Alonso-García, Miriam | es |
dc.creator | Sánchez-Gastaldo, Amparo | es |
dc.creator | Muñoz-Fuentes, Miguel A. | es |
dc.creator | Molina-Pinelo, Sonia | es |
dc.creator | Boyero, Laura | es |
dc.creator | Benedetti, Johana Cristina | es |
dc.creator | Bernabé-Caro, Reyes | es |
dc.date.accessioned | 2022-11-25T16:58:14Z | |
dc.date.available | 2022-11-25T16:58:14Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Alonso-García, M., Sánchez-Gastaldo, A., Muñoz-Fuentes, M.A., Molina-Pinelo, S., Boyero, L., Benedetti, J.C. y Bernabé-Caro, R. (2022). Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Pharmaceuticals, 15 (5), 533. https://doi.org/10.3390/ph15050533. | |
dc.identifier.issn | 1424-8247 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139816 | |
dc.description.abstract | Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown
superior survival outcomes and improved adverse effects compared to standard chemotherapy in
advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has
not been directly compared in clinical trials. This retrospective, single-centre study was performed
from June 2015 to December 2020 and included a cohort of 158 previously treated patients with
stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab)
(n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR)
was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate
analysis did not show significant differences between the two groups for PFS and OS (PFS hazard
ratio (HR): 0.80, 95% confidence interval (CI): 0.55–1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52–1.21,
p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and
in 34 patients in the atezolizumab group (49.3%) (p < 0.001). Atezolizumab and nivolumab did not
show statistically significant differences in survival outcomes in patients with NSCLC, even when
stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis
suggested a more favourable toxicity profile for atezolizumab. | es |
dc.format | application/pdf | es |
dc.format.extent | 14 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Pharmaceuticals, 15 (5), 533. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Atezolizumab | es |
dc.subject | Immune checkpoint inhibitors (ICIs) | es |
dc.subject | Immunotherapy | es |
dc.subject | Nivolumab | es |
dc.subject | Non small cell lung cancer (NSCLC) | es |
dc.subject | Real-world data | es |
dc.title | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | PI-0046-2012 | es |
dc.relation.projectID | PY20_00992 | es |
dc.relation.projectID | PI17/00033 | es |
dc.relation.projectID | PI20/01109 | es |
dc.relation.publisherversion | https://www.mdpi.com/1424-8247/15/5/533 | es |
dc.identifier.doi | 10.3390/ph15050533 | es |
dc.contributor.group | Universidad de Sevilla. CTS629: Oncología molecular y nuevas terapias. | es |
dc.journaltitle | Pharmaceuticals | es |
dc.publication.volumen | 15 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 533 | es |
dc.contributor.funder | Consejería de Sanidad y Bienestar Social, Junta de Andalucía | es |
dc.contributor.funder | Plan Andaluz de Investigación, Desarrollo e Innovación, Junta de Andalucía | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |